½ÃÀ庸°í¼­
»óǰÄÚµå
1437946

¼¼°èÀÇ ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀå : Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Global Cardiovascular Ultrasound System - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ(Cardiovascular Ultrasound System) ½ÃÀå ±Ô¸ð´Â 2024³â 14¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 18¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£(2024-2029³â) Áß 5.41%ÀÇ CAGR·Î ÃßÀÌÇÏ¸ç ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ-½ÃÀå

COVID-19´Â Àü ¼¼°è¿¡ »ó»óÇÒ ¼ö ¾ø´Â ¿µÇâÀ» ¹ÌÃÆ°í ÀÇ·á »ê¾÷ÀÇ °ÅÀÇ ¸ðµç Ãø¸éÀ» º¯È­½ÃÄ×½À´Ï´Ù. ÆÒµ¥¹ÍÀº ÃÊÀ½ÆÄ ½ÃÀå¿¡µµ º¹ÀâÇϰí Àü·Ê ¾ø´Â ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº ÁÖ·Î ÇöÀå Áø·á(POC) ¾ÖÇø®ÄÉÀ̼ÇÀ» ÅëÇØ COVID-19 ȯÀÚÀÇ ºÐ·ù, ¸ð´ÏÅ͸µ ¹× Áø´ÜÀ» À§ÇØ ÃÊÀ½ÆÄ Áø´ÜÀÇ ÀáÀç·ÂÀ» Ȱ¿ëÇß½À´Ï´Ù. 2021³â 3¿ù¿¡ ¹ßÇ¥µÈ 'COVID-19 °¨¿°¿¡¼­ ÇöÀå Áø·á ½ÉÀå ÃÊÀ½ÆÄÀÇ Àû¿ë'À̶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡ µû¸£¸é ´ÙÀ½°ú °°½À´Ï´Ù: Ãʱ⠰æÇè¿¡¼­ ¾òÀº ±³ÈÆ'¿¡ µû¸£¸é, COVID-19 °¨¿° ȯÀÚ¿¡¼­ ±Þ¼º ½ÉÀå ¼Õ»óÀÇ À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ ÇöÀå Áø·á ½ÉÀå ÃÊÀ½ÆÄ(PoCCUS)´Â COVID-19 °¨¿° ȯÀÚÀÇ Á¾´ÜÀû ¸ð´ÏÅ͸µ¿¡ »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. COVID-19 ȯÀÚ¿¡¼­ ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛÀÇ Àû¿ëÀ» ÀÔÁõÇÏ´Â ÀÌ·¯ÇÑ ¿¬±¸´Â ½ÃÀå ¼ºÀåÀ» ±àÁ¤ÀûÀ¸·Î µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ½ÉÇ÷°ü Áúȯ(CVD) ¹ß»ý·ü Áõ°¡, ±â¼ú ¹ßÀü, ħ½ÀÀû ½ÉÀå Áø´Ü ÀýÂ÷¿¡ ´ëÇÑ ½ÉÃÊÀ½ÆÄÀÇ ÀåÁ¡ µîÀÌ ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)ÀÇ 2021³â 6¿ù ¾÷µ¥ÀÌÆ®¿¡ µû¸£¸é ½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°è ÁÖ¿ä »ç¸Á ¿øÀÎÀ̸ç, ½ÉÇ÷°ü ÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÇ ¾à 4ºÐÀÇ 3ÀÌ Àú¼Òµæ ¹× Áß°£ ¼Òµæ ±¹°¡¿¡¼­ ¹ß»ýÇϰí ÀÖ¾î ½ÉÇ÷°ü ÁúȯÀ¸·Î ÀÎÇÑ ³ôÀº »ç¸Á·ü·Î ÀÎÇØ Áúº´ Áø´Ü ¹× ¸ð´ÏÅ͸µ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ 2022³â ¹Ì±¹½ÉÀåÇùȸ(AHA) º¸°í¼­¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î ¾à 2¾ï 4,410¸¸ ¸íÀÌ ÇãÇ÷¼º ½ÉÀåÁúȯ(IHD)À» ¾Î°í ÀÖÀ¸¸ç, ºÏ¾ÆÇÁ¸®Ä«¿Í Áßµ¿, Áß¾Ó ¹× ³²¾Æ½Ã¾Æ, µ¿À¯·´Àº 2020³â ¼¼°è¿¡¼­ °¡Àå ³ôÀº IHD À¯º´·üÀ» º¸¿´½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ãÀº °íÇ÷¾Ð, ºñ¸¸, Èí¿¬, ´ç´¢º´ µî°ú °°Àº °ü·Ã À§Çè ¿äÀÎÀÇ ³ôÀº À¯º´·ü°ú ÁÂ½Ä »ýȰ ¹æ½ÄÀ¸·Î ÀÎÇØ ´õ¿í Áõ°¡ ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¹Ç·Î Áúº´ Áø´Ü, ¸ð´ÏÅ͸µ ¹× Ä¡·á¿¡ ÃÊÀ½ÆÄ »ç¿ëÀÌ Áõ°¡ÇÏ¿© ¿¹Ãø ±â°£ µ¿¾È ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀå ¼ºÀåÀ» ÁÖµµ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àΰø Áö´É°ú °°Àº ±â¼ú ¹ßÀüÀº ƯÁ¤ ½ÉÀå ÁúȯÀ» Áø´ÜÇÏ´Â ´É·ÂÀ» Çâ»ó½ÃÄÑ ½ÉÀåÇп¡ »ó´çÇÑ ±àÁ¤Àû ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 10¿ù GEÇコÄɾî´Â ÀÓ»óÀǰ¡ ´õ ºü¸£°í ¹Ýº¹ °¡´ÉÇÑ °Ë»ç¸¦ ÀϰüµÇ°Ô ¼öÇàÇÒ ¼ö ÀÖ´Â ÀΰøÁö´É(AI) ±â¹ÝÀÇ »õ·Î¿î ±â´ÉÀÌ Æ÷ÇÔµÈ »ý»ýÇÑ ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ ¿ïÆ®¶ó ¿¡µð¼Ç ÆÐŰÁö¿¡ ´ëÇØ ¹Ì±¹ ½ÄǰÀǾ౹(FDA) Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù.

±×·¯³ª ºÒ¸®ÇÑ »óȯ ½Ã³ª¸®¿À¿Í ½Å±â¼úÀÇ Ã¤ÅÃÀ¸·Î ÀÎÇÑ °æÁ¦Àû ¿µÇâÀº ¿¹Ãø ±â°£ µ¿¾È Á¶»çµÈ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÉÀåÇ÷°ü ÃÊÀ½ÆÄ Áø´Ü ÀåÄ¡ ½ÃÀå µ¿Çâ

2D ÃÊÀ½ÆÄ À̹Ì¡ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÎ¹®ÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2D ÃÊÀ½ÆÄ À̹Ì¡Àº B-¸ðµå ¿¡ÄÚ±×·¡ÇÇ ¶Ç´Â ¼Ò³ë±×·¡ÇǶó°íµµ ÇÕ´Ï´Ù. B ¸ðµå µ¥ÀÌÅÍÀÇ 2D ¸ÊÀ» Ç¥½ÃÇϸç ÇöÀç Àü ¼¼°èÀûÀ¸·Î °¡Àå ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ½ÉÀå ÃÊÀ½ÆÄ ¿µ»ó ÇüÅÂÀÔ´Ï´Ù. ¿©·¯ °³ÀÇ Æ®·£½ºµà¼­¸¦ »ç¿ëÇÕ´Ï´Ù. È­¸é¿¡ ¸ÅÃʸ¶´Ù ¿©·¯ ÀåÀÇ À̹ÌÁö ¶Ç´Â ÇÁ·¹ÀÓÀ» »ý¼ºÇÏ¿© ¸¶Ä¡ ¿òÁ÷ÀÌ´Â °Íó·³ º¸ÀÌ°Ô ÇÕ´Ï´Ù. ÁÖ·Î ½É½Ç Ä¡¼ö¸¦ ÃøÁ¤ÇÏ°í ÆÇ¸· ±¸Á¶¿Í ±â´ÉÀ» Æò°¡ÇÏ¸ç µµÇ÷¯ ¾ç½ÄÀÇ ÇØ¼® Á¤È®µµ¸¦ Çâ»ó½ÃŰ´Â µ¥ »ç¿ëµË´Ï´Ù. 2D ÃÊÀ½ÆÄ´Â °¡Àå ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ±â¼ú Áß ÇϳªÀÔ´Ï´Ù.

½ÉÇ÷°ü ÁúȯÀÇ ³ôÀº À¯º´·ü°ú 2D ÃÊÀ½ÆÄ ½Ã½ºÅÛÀÇ ±¤¹üÀ§ÇÑ ¼ö¿ë ¹× »ç¿ëÀ¸·Î ÀÎÇØ ÀÌ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ½ÉÀå Çùȸ (AHA)ÀÇ 2022 ³â º¸°í¼­¿¡ µû¸£¸é 2020 ³â¿¡ ¾à 6820 ¸¸ °ÇÀÇ ÇãÇ÷¼º ³úÁ¹Áß, 1890 ¸¸ °ÇÀÇ ³ú³» ÃâÇ÷, 810 ¸¸ °ÇÀÇ ÁöÁÖ¸· ÇÏ ÃâÇ÷ÀÌ ¹ß»ýÇÏ¿© Àü³â ´ëºñ Áõ°¡ÇßÀ¸¸ç µû¶ó¼­ CVDÀÇ ³ôÀº ºÎ´ãÀ¸·Î ÀÎÇØÀÌ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ 2020³â 10¿ù, Royal Philips´Â ÀÏ¹Ý ¿µ»ó ¹× ½ÉÇ÷°ü ¿µ»ó ÀýÂ÷¿¡ ¸ÂÃãÈ­µÈ »õ·Î¿î Çõ½ÅÀû ÃÊÀ½ÆÄ ½Ã¸®ÁîÀÎ ÃÊÀ½ÆÄ 3300À» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç° ¹ßÀüÀº ÇâÈÄ ¸î ³â µ¿¾È ¼öÁ÷Àû ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

µû¶ó¼­ ÀÌ ºÎ¹®Àº À§ÀÇ ¿äÀεé·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹Ãø±â°£ Áß ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»ó

ºÏ¹Ì´Â ÀÏ¹Ý Áø´Ü¿¡¼­ ÃÊÀ½ÆÄ ¹æ½ÄÀÇ ³ôÀº äÅ÷ü°ú »ýȰ½À°üº´ °ü·Ã ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±â¼úÀûÀ¸·Î Áøº¸µÈ ÀÇ·á ±â±â¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä´Â ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ³úÁ¹Áß ¹× ½É±Ù º´Áõ°ú °°Àº ´Ù¾çÇÑ °ü»ó µ¿¸Æ ½ÉÀå ÁúȯÀÇ Àü ¼¼°èÀû ºÎ´ãÀÌ Áõ°¡ÇÏ¿© ½ÉÀå °ü·Ã »ç¸ÁÀÇ Àü ¼¼°èÀû ºÎ´ãÀ» À¯¹ßÇÑ´Ù´Â °ÍÀÔ´Ï´Ù. ¹Ì±¹ Áúº´ÅëÁ¦¼¾ÅÍ(CDC)ÀÇ º¸°í¼­¿¡ µû¸£¸é 2021³â¿¡ ¾÷µ¥ÀÌÆ®µÈ Åë°è¿¡ µû¸£¸é 40Ãʸ¶´Ù ¹Ì±¹ÀÎ ÇÑ ¸íÀÌ ½ÉÀ帶ºñ¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½Ã³ª¸®¿À´Â ´õ ³ªÀº Áø´ÜÀ» À§ÇÑ ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ¿¡ ´ëÇÑ ´õ ³ôÀº ¼ö¿ä·Î À̾îÁ® ¹Ì±¹ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀÔ´Ï´Ù.

°Ô´Ù°¡ 2020³â 10¿ù, GE Healthcare´Â ÀÓ»óÀǰ¡ ´õ ºü¸£°í ¹Ýº¹ °¡´ÉÇÑ °Ë»ç¸¦ ÀϰüµÇ°Ô ¼öÇàÇÒ ¼ö ÀÖµµ·Ï ÀΰøÁö´É(AI) ±â¹ÝÀÇ »õ·Î¿î ±â´ÉÀ» Æ÷ÇÔÇÏ´Â »ý»ýÇÑ ½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛÀÇ ¿ïÆ®¶ó ¿¡µð¼Ç ÆÐŰÁö¿¡ ´ëÇØ ¹Ì±¹ ½ÄǰÀǾ౹À¸·ÎºÎÅÍ 510k Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ 2020³â 9¿ù, Çʸ³½º ÇコÄɾî´Â ½ÉÀå³»°ú¿¡¼­ ´õ ¸¹Àº ȯÀÚ¿¡°Ô Çâ»óµÈ È¿À²¼º°ú 󸮷®À¸·Î ´õ ³ªÀº Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇϱâ À§ÇØ Àü¿ë ½ÉÇ÷°ü ÃÊÀ½ÆÄ ¼Ö·ç¼ÇÀÎ Affiniti CVx¸¦ ÃֽйöÀüÀ¸·Î Ãâ½ÃÇß½À´Ï´Ù.

¶ÇÇÑ, Áúº´ ÀνÄÀ» À§ÇÑ ÀÎ½Ä Á¦°í ÀÌ´Ï¼ÅÆ¼ºê´Â ºÏ¹ÌÀÇ ½ÉÇ÷°ü ±â±â ½ÃÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 2¿ù ¸ß½ÃÄÚ´Â CVD¿¡ ´ëÇÑ 1Â÷ ÀǷḦ °­È­Çϱâ À§ÇØ HEARTS ÀÌ´Ï¼ÅÆ¼ºê¿¡ °¡ÀÔÇß½À´Ï´Ù. ¹ü¹Ìº¸°Ç±â±¸/¼¼°èº¸°Ç±â±¸(PAHO/WHO)°¡ ÃßÁøÇÏ´Â ÀÌ ÀÌ´Ï¼ÅÆ¼ºê´Â 1Â÷ ÀÇ·á ¼öÁØ¿¡¼­ °íÇ÷¾ÐÀÇ ¿¹¹æ°ú °ü¸®¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

µû¶ó¼­ À§ÀÇ ¿äÀεé·Î ÀÎÇØ ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÉÇ÷°ü ÃÊÀ½ÆÄ ½Ã½ºÅÛ »ê¾÷ °³¿ä

Á¶»ç ´ë»ó ½ÃÀåÀº Å©°í ÀÛÀº ½ÃÀå Ç÷¹À̾îµéÀÌ Àֱ⠶§¹®¿¡ Àû´çÈ÷ ÅëÇյǾî ÀÖ½À´Ï´Ù. ½ÃÀå Âü¿©Àڷδ Canon Medical Systems, Chison, Esaote SpA, GE Healthcare, Hitachi Medical Corporation, Koninklijke Philips NV, Health Catalyst(KPI Health Care Inc.), Samsung Healthcare, Siemens Healthcare, Whale Imaging µîÀÌ ÀÖ½À´Ï´Ù. Áö¿ª ¹× ¼­ºñ½º Æ÷Æ®Æú¸®¿À È®´ë ¹× ÇÕº´ ¹× Àμö´Â ÀÌ·¯ÇÑ ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â Áß¿äÇÑ Àü·«Àû ³ë·ÂÀÔ´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ùÀÇ ¾Ö³Î¸®½ºÆ® ¼­Æ÷Æ®

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»ç ÀüÁ¦ Á¶°Ç ¹× ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ
    • ½ÉÇ÷°üÁúȯ(CVD) ¹ß»ý·ü Áõ°¡
    • ±â¼ú Áøº¸ÀÇ ÁøÀü
    • ħ½ÀÀû ½ÉÀå Áø´Ü ÀýÂ÷¿¡ ´ëÇÑ ½É ÃÊÀ½ÆÄ °Ë»çÀÇ ÀåÁ¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ
    • ºÒ¸®ÇÑ »óȯ ½Ã³ª¸®¿À
    • ½Å±â¼ú µµÀÔÀ¸·Î ÀÎÇÑ °æÁ¦Àû ¿µÇâ
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ´ëü Á¦Ç°ÀÇ À§Çù
    • ±â¾÷ °£ °æÀï Á¤µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Å×½ºÆ® À¯Çüº°
    • °æÈ亮 ½ÉÀå ÃÊÀ½ÆÄ °Ë»ç
    • °æ½Äµµ ½ÉÀå ÃÊÀ½ÆÄ °Ë»ç
    • ½ºÆ®·¹½º ½ÉÀå ÃÊÀ½ÆÄ °Ë»ç
    • ±âŸ Å×½ºÆ® À¯Çü
  • ±â¼úº°
    • 2D
    • 3D¿Í 4D
    • µµÇ÷¯ À̹Ì¡
  • µð¹ÙÀ̽ºº° Ç¥½Ã
    • Ä÷¯ µð½ºÇ÷¹ÀÌ
    • Èæ¹é(B/W) µð½ºÇ÷¹ÀÌ
  • ÃÖÁ¾ »ç¿ëÀÚº°
    • º´¿ø
    • ¿Ü·¡¼¾ÅÍ
    • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ
  • Áö¿ªº°
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾Æ ÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Canon Medical Systems
    • Chison
    • Clarius Mobile Health
    • Esaote SpA
    • GE Healthcare
    • FUJIFILM Holdings Corporation
    • Koninklijke Philips NV
    • Medisono LLC
    • Samsung Healthcare
    • Siemens Healthcare GmbH
    • Whale Imaging

Á¦7Àå ½ÃÀå ±âȸ ¹× ÇâÈÄ µ¿Çâ

LYJ

The Global Cardiovascular Ultrasound System Market size is estimated at USD 1.44 billion in 2024, and is expected to reach USD 1.89 billion by 2029, growing at a CAGR of 5.41% during the forecast period (2024-2029).

Global Cardiovascular Ultrasound System - Market

COVID-19 had an unimaginable impact on the world and altered almost every aspect of the healthcare industry. The pandemic also had a complex and unprecedented effect on the ultrasound market. Healthcare providers deployed the potential of ultrasound diagnosis, primarily for point-of-care (POC) applications, for the triage, monitoring, and diagnosis of COVID-19 patients. As per the study published in March 2021, titled 'Application of Point-of-care Cardiac Ultrasonography in COVID-19 Infection: Lessons Learned from the Early Experience', since there is a high prevalence of acute cardiac injury in patients with COVID-19 infection, point-of-care cardiac ultrasound (PoCCUS) may be used for longitudinal monitoring of patients infected with COVID-19. Such studies demonstrating the application of cardiovascular ultrasound systems in COVID-19 patients are expected to positively support the growth of the market.

The major factors supporting the growth of the cardiovascular ultrasound system market include the increasing incidence of cardiovascular diseases (CVDs), technological advancements, and the advantages of echocardiography over invasive cardiac diagnostic procedures.

According to the June 2021 update of the World Health Organization (WHO), cardiovascular diseases are the leading cause of death around the world, and about three-quarters of deaths from CVDs are recorded in low- and middle-income countries and thus, due to the high mortality due to the CVDs, the demand for disease diagnostics and monitoring is increasing which is expected to fuel growth in the cardiovascular ultrasound system market. Further, according to the 2022 American Heart Association (AHA) report, approximately 244.1 million people were living with ischemic heart disease (IHD) around the world, and North Africa and the Middle East, Central and South Asia, and Eastern Europe had the highest prevalence rates of IHD in the world in 2020. This burden of cardiovascular diseases is further expected to increase due to the high prevalence of associated risk factors such as hypertension, obesity, smoking, diabetes, and others, along with the sedentary lifestyle; thus, the use of ultrasound in disease diagnostics, monitoring, and treatment is expected to increase which will drive growth in the cardiovascular ultrasound system market over the forecast period.

Technological advancements such as artificial intelligence have a significant positive impact on cardiology with improved ability to diagnose certain heart conditions. For instance, in October 2020, GE Healthcare received the United States Food and Drug Administration clearance for its ultra edition package of vivid cardiovascular ultrasound systems, which includes new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently.

However, unfavorable reimbursement scenarios and the economic impact of adopting new technologies are likely to impede the studied market growth over the forecast period.

Cardiovascular Ultrasound System Market Trends

The 2D Ultrasound Imaging Segment is Expected to be Fastest Growing Segment Over the Forecast Period

2D ultrasound imaging is also known as B-mode echography or sonography. It displays a 2D map of B-mode data and is currently the most common form of cardiac ultrasound imaging used worldwide. It uses multiple transducers. It enables the generation of multiple images of the field or frames every second on the screen, giving an illusion of movement. It is primarily used to measure cardiac chamber dimensions, assess valvular structure and function, and improve the accuracy of interpretation of Doppler modalities. 2D ultrasound is one of the most common forms of technology used.

Owing to the high prevalence of cardiovascular diseases and wide acceptance and usage of 2D ultrasound systems, the segment is expected to grow significantly over the forecast period. For instance, according to the 2022 report of the American Heart Association (AHA), there were about 68.2 million ischemic stroke cases, 18.9 million intracerebral hemorrhages, and 8.1 million cases of subarachnoid hemorrhages in 2020 which has increased from the previous year and thus, owing to the high burden of the CVDs, the segment is expected to grow over the forecast period.

Moreover, in October 2020, Royal Philips launched the Ultrasound 3300, a new innovative ultrasound series tailored for general Imaging and cardiovascular imaging procedures. Such product advancement will boost vertical growth over the coming years.

Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.

North America is Expected to Dominate the Market Over the Forecast Period

North America is anticipated to lead the market owing to the high adoption of ultrasound modality in general diagnostics and the rising prevalence of lifestyle-associated chronic diseases. The high demand for technologically advanced medical devices is expected to propel market growth in the region.

The major factor driving the market is the rising global burden of various coronary heart diseases, such as stroke and cardiomyopathy, which cause a global burden of cardiac-related deaths. As per a report by the United States Centers for Disease Control (CDC), statistics updated in 2021, every 40 seconds, an American may have a heart attack. This scenario leads to a higher demand for cardiovascular ultrasound systems for better diagnosis, which will drive the market in the United States.

Moreover, in October 2020, GE Healthcare received the United States Food and Drug Administration's 510k clearance for its ultra-edition package of vivid cardiovascular ultrasound systems, which include new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently. Also, in September 2020, Philips Healthcare introduced the latest addition of dedicated cardiovascular ultrasound solutions, the Affiniti CVx, to support the cardiology departments in delivering better care to more patients with increased efficiency and throughput.

Furthermore, supportive awareness initiatives for disease awareness are projected to support the market for cardiovascular devices in North America. For instance, in February 2020, Mexico joined the HEARTS initiative to strengthen primary healthcare for CVD. Promoted by the Pan American Health Organization/ World Health Organization (PAHO/WHO), the initiative aims to improve the prevention and control of hypertension at the primary care level.

Thus, owing to the abovementioned factors, the North American region is expected to show lucrative growth over the forecast period.

Cardiovascular Ultrasound System Industry Overview

The market studied is moderately consolidated, owing to the presence of many small and large market players. Some market players are Canon Medical Systems, Chison, Esaote SpA, GE Healthcare, Hitachi Medical Corporation, Koninklijke Philips NV, Health Catalyst (KPI Healthcare Inc.), Samsung Healthcare, Siemens Healthcare, and Whale Imaging. Regional and service portfolio expansions and mergers and acquisitions are key strategic undertakings adopted by these players.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Cardiovascular Diseases (CVDs)
    • 4.2.2 Rise in Technological Advancements
    • 4.2.3 Advantages of Echocardiography over Invasive Cardiac Diagnostic Procedures
  • 4.3 Market Restraints
    • 4.3.1 Unfavorable Reimbursement Scenario
    • 4.3.2 Economic Impact of Adopting New Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Test Type
    • 5.1.1 Transthoracic Echocardiogram
    • 5.1.2 Transesophageal Echocardiogram
    • 5.1.3 Stress Echocardiogram
    • 5.1.4 Other Test Types
  • 5.2 By Technology
    • 5.2.1 2D
    • 5.2.2 3D and 4D
    • 5.2.3 Doppler Imaging
  • 5.3 By Device Display
    • 5.3.1 Color Display
    • 5.3.2 Black and White (B/W) Display
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Centers
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Canon Medical Systems
    • 6.1.2 Chison
    • 6.1.3 Clarius Mobile Health
    • 6.1.4 Esaote SpA
    • 6.1.5 GE Healthcare
    • 6.1.6 FUJIFILM Holdings Corporation
    • 6.1.7 Koninklijke Philips NV
    • 6.1.8 Medisono LLC
    • 6.1.9 Samsung Healthcare
    • 6.1.10 Siemens Healthcare GmbH
    • 6.1.11 Whale Imaging

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦